000 02130 a2200601 4500
005 20250513232721.0
264 0 _c20010426
008 200104s 0 0 eng d
022 _a1524-4563
024 7 _a10.1161/01.hyp.37.2.787
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aFiebeler, A
245 0 0 _aMineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
_h[electronic resource]
260 _bHypertension (Dallas, Tex. : 1979)
_cFeb 2001
300 _a787-93 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAldosterone
_xblood
650 0 4 _aAngiotensin II
_xgenetics
650 0 4 _aAnimals
650 0 4 _aAnimals, Genetically Modified
650 0 4 _aBlood Pressure
_xdrug effects
650 0 4 _aBody Weight
650 0 4 _aCardiovascular Diseases
_xchemically induced
650 0 4 _aFibroblast Growth Factor 2
_xgenetics
650 0 4 _aHeart
_xdrug effects
650 0 4 _aImmunohistochemistry
650 0 4 _aMineralocorticoid Receptor Antagonists
650 0 4 _aNF-kappa B
_xmetabolism
650 0 4 _aOrgan Size
650 0 4 _aPlatelet-Derived Growth Factor
_xmetabolism
650 0 4 _aRNA, Messenger
_xmetabolism
650 0 4 _aRats
650 0 4 _aReceptors, Mineralocorticoid
_xphysiology
650 0 4 _aRenin
_xgenetics
650 0 4 _aReverse Transcriptase Polymerase Chain Reaction
650 0 4 _aSpironolactone
_xpharmacology
650 0 4 _aTetrazoles
_xpharmacology
650 0 4 _aTranscription Factor AP-1
_xmetabolism
650 0 4 _aTransforming Growth Factor beta
_xmetabolism
650 0 4 _aValine
_xanalogs & derivatives
650 0 4 _aValsartan
700 1 _aSchmidt, F
700 1 _aMüller, D N
700 1 _aPark, J K
700 1 _aDechend, R
700 1 _aBieringer, M
700 1 _aShagdarsuren, E
700 1 _aBreu, V
700 1 _aHaller, H
700 1 _aLuft, F C
773 0 _tHypertension (Dallas, Tex. : 1979)
_gvol. 37
_gno. 2 Pt 2
_gp. 787-93
856 4 0 _uhttps://doi.org/10.1161/01.hyp.37.2.787
_zAvailable from publisher's website
999 _c11167880
_d11167880